Cargando…
Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP)
BACKGROUND: In the current study, we aimed to investigate the efficacy and safety of intravenous immunoglobulin (IVIg)-SN 10%, a new 10% IVIg formulation, in adult patients with severe primary immune thrombocytopenia (ITP; platelet count < 20 × 10(9)/L). METHODS: Patients diagnosed as primary ITP...
Autores principales: | Hong, Junshik, Bang, Soo-Mee, Mun, Yeung-Chul, Yhim, Ho-Young, Lee, Jaehoon, Lim, Hyeong-Seok, Oh, Doyeun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934518/ https://www.ncbi.nlm.nih.gov/pubmed/29736158 http://dx.doi.org/10.3346/jkms.2018.33.e142 |
Ejemplares similares
-
Intravenous Immunoglobulin (IVIg) Utilization in Immune Thrombocytopenia (ITP): A Multi-Center, Retrospective Review
por: Hsia, Cyrus C., et al.
Publicado: (2015) -
Incidence of venous thromboembolism in Korea from 2009 to 2013
por: Hong, Junshik, et al.
Publicado: (2018) -
Management of immune thrombocytopenia: Korean experts recommendation in 2017
por: Jang, Jun Ho, et al.
Publicado: (2017) -
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
por: Zufferey, Anne, et al.
Publicado: (2017) -
The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
por: Hughes, David
Publicado: (2022)